Natixis Advisors LLC Has $5.74 Million Holdings in Integer Holdings Co. (NYSE:ITGR)

Natixis Advisors LLC lessened its stake in Integer Holdings Co. (NYSE:ITGR) by 3.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,278 shares of the medical equipment provider’s stock after selling 1,770 shares during the quarter. Natixis Advisors LLC owned about 0.13% of Integer worth $5,735,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ITGR. Mather Group LLC. raised its stake in Integer by 304.3% in the fourth quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 143 shares in the last quarter. R Squared Ltd bought a new position in Integer in the fourth quarter valued at about $44,000. Versant Capital Management Inc grew its position in Integer by 98.4% in the fourth quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock valued at $49,000 after acquiring an additional 183 shares during the last quarter. Principal Securities Inc. grew its position in Integer by 31.2% in the fourth quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider’s stock valued at $85,000 after acquiring an additional 152 shares during the last quarter. Finally, Contravisory Investment Management Inc. grew its position in Integer by 210.8% in the fourth quarter. Contravisory Investment Management Inc. now owns 693 shares of the medical equipment provider’s stock valued at $92,000 after acquiring an additional 470 shares during the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Price Performance

Integer stock opened at $115.07 on Friday. The stock’s 50 day moving average is $132.59 and its 200 day moving average is $132.31. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. The firm has a market cap of $3.87 billion, a P/E ratio of 34.25, a P/E/G ratio of 1.72 and a beta of 1.24. Integer Holdings Co. has a one year low of $107.11 and a one year high of $146.36.

Integer (NYSE:ITGR) last posted its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). The company had revenue of $449.50 million during the quarter, compared to analyst estimates of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. As a group, research analysts expect that Integer Holdings Co. will post 6.01 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ITGR shares. Benchmark lifted their target price on Integer from $140.00 to $150.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Wells Fargo & Company reiterated an “overweight” rating and issued a $160.00 target price on shares of Integer in a research report on Tuesday, December 3rd. Truist Financial lifted their target price on Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Citigroup boosted their price target on Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a report on Wednesday, December 11th. Finally, KeyCorp boosted their price target on Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $149.00.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.